Literature DB >> 15082751

Behavior of alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier.

V Monnaert1, S Tilloy, H Bricout, L Fenart, R Cecchelli, E Monflier.   

Abstract

Cyclodextrins (CDs) can be envisaged to cure some diseases related to the brain, but the behavior of these compounds toward the blood-brain barrier (BBB) remains largely unexplored to envisage such clinical applications. To fulfill this gap, the toxicity and endothelial permeability for native, methylated, and hydroxypropylated alpha-, beta-, and gamma-CDs have been studied on an in vitro model of BBB. As shown by the endothelial permeability for sucrose and immunofluorescence stainings, the native CDs are the most toxic CDs (alpha- > beta- > gamma-CD). Whereas the chemical modification of beta-CD did not affect the toxicity of this CD, differences are observed for the alpha- and gamma-CD. To determine the origin of toxicity, lipid effluxes on the brain capillary endothelial cells were performed in the presence of native CDs. It was found that alpha-CD removed phospholipids and that beta-CD extracted phospholipids and cholesterol. gamma-CD was less lipid-selective than the other CDs. Finally, the endothelial permeability of each CD has been determined. Surprisingly, no structure/permeability relationship has been observed according to the nature and chemical modifications of CDs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082751     DOI: 10.1124/jpet.104.067512

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  Diverse presynaptic mechanisms underlying methyl-β-cyclodextrin-mediated changes in glutamate transport.

Authors:  Tatiana Borisova; Roman Sivko; Arseniy Borysov; Natalia Krisanova
Journal:  Cell Mol Neurobiol       Date:  2010-05-26       Impact factor: 5.046

2.  2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease.

Authors:  Sarah Ward; Patricia O'Donnell; Steven Fernandez; Charles H Vite
Journal:  Pediatr Res       Date:  2010-07       Impact factor: 3.756

3.  Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood-brain barrier permeability.

Authors:  Charles C Pontikis; Cristin D Davidson; Steven U Walkley; Frances M Platt; David J Begley
Journal:  J Inherit Metab Dis       Date:  2013-02-15       Impact factor: 4.982

4.  The effect of sterol structure upon clathrin-mediated and clathrin-independent endocytosis.

Authors:  Ji Hyun Kim; Ashutosh Singh; Maurizio Del Poeta; Deborah A Brown; Erwin London
Journal:  J Cell Sci       Date:  2017-06-27       Impact factor: 5.285

5.  Cyclodextrin induces calcium-dependent lysosomal exocytosis.

Authors:  Fannie W Chen; Chunlei Li; Yiannis A Ioannou
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

Review 6.  Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies.

Authors:  Raphael Zidovetzki; Irena Levitan
Journal:  Biochim Biophys Acta       Date:  2007-04-06

7.  Membrane cholesterol depletion as a trigger of Nav1.9 channel-mediated inflammatory pain.

Authors:  Muriel Amsalem; Corinne Poilbout; Géraldine Ferracci; Patrick Delmas; Francoise Padilla
Journal:  EMBO J       Date:  2018-02-19       Impact factor: 11.598

8.  Cyclodextrins inhibit replication of scrapie prion protein in cell culture.

Authors:  Marguerite Prior; Sylvain Lehmann; Man-Sun Sy; Brendan Molloy; Hilary E M McMahon
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

9.  Membrane Structure-Function Insights from Asymmetric Lipid Vesicles.

Authors:  Erwin London
Journal:  Acc Chem Res       Date:  2019-08-06       Impact factor: 22.384

10.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.